Strategic Scale Ze Vacor operates within a non-profit healthcare system (IHS) and focuses on PET/SPECT radiopharmaceuticals, suggesting opportunities in provider-driven procurement, radiopharmaceutical supply contracts, and educational services for nuclear medicine programs.

Imaging Focus With ongoing development of a 70 MeV cyclotron and expanded synthesis/processing units, there is potential to offer radiopharmaceutical production services, regulatory-compliant labeling, and custom tracer development to hospitals, universities, and biotechs expanding molecular imaging capabilities.

Regional Hub Headquartered in Dulles/Noblesville with a broad service footprint nationwide via Zevacor Pharma, sales opportunities exist in distributing clinical and research radioisotopes to diverse imaging centers and research institutions across the United States.

End-to-End Solutions Combine manufacturing, distribution, and educational services to offer bundled solutions for nuclear medicine departments, including training, protocol optimization, quality control, and compliance support to improve patient care outcomes.

Growth Signals As a subsidiary under IHS and with a revenue range of mid single to low double digits, there is room to position Zevacor as a scalable supplier partner for institutional buyers seeking reliable radiopharmaceuticals and related services in a consolidating market.